Tumor‐induced osteomalacia:​ treatment progress using burosumab, an anti‐FGF23 monoclonal antibody

wbldb

Tumor‐induced osteomalacia: treatment progress using burosumab, an anti‐FGF23 monoclonal antibody

J Bone Miner Res. April 2021;36(4):625-626

Cited Works (3)

Year	Entry
2021	Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim analysis of a phase 2 open‐label trial assessing burosumab efficacy and safety in patients with tumor‐induced osteomalacia. J Bone Miner Res. February 2021;36(2):262-270.
2020	Smith PS, Gottesman GS, Zhang F, Cook F, Ramirez B, Wenkert D, Wollberg V, Huskey M, Mumm S, Whyte MP. X‐linked hypophosphatemia: uniquely mild disease associated with PHEX 3′‐UTR mutation c.231A>G (a retrospective case–control study). J Bone Miner Res*. May 2020;35(5):920-931.
2021	Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the treatment of tumor‐induced osteomalacia. J Bone Miner Res. April 2021;36(4):627-635.